Key Drivers Accelerating the Cancer biomarker Market Growth
Several factors are fueling growth in the Cancer biomarker Market. Rising cancer cases, coupled with the need for early detection, are driving adoption of biomarker-based tests. Additionally, pharmaceutical companies are using biomarkers to improve drug development success rates.
Government initiatives promoting cancer research and increasing awareness about precision medicine are further boosting demand. Growing collaborations between diagnostic firms and biopharma players ensure wider adoption of advanced biomarker solutions.
Market Outlook: The cancer biomarker market was worth USD 15.9 billion in 2022 and will grow to USD 27.8 billion by 2030, at a 9.8% CAGR. This trajectory reflects the strong clinical and commercial demand.
1 View